Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors.
Gingival overgrowth (GO) is the main oral manifestation in transplant recipients who use calcineurin inhibitors. In the present study, factors for GO development were investigated in Brazilian renal transplant recipients who were prescribed cyclosporine (CsA) or tacrolimus (TAC). Demographic, pharmacological, clinical, and periodontal data were obtained from 83 patients, as well as HLA expression in 51 of them. The prevalence of GO was high (47%), but its severity was low according to periodontal indices. The prevalence of GO was greater among patients who used CsA (n = 49) than those receiving used TAC (n = 34) namely, 61% versus 26.5% (P = .003). Comparisons between patients with versus without GO were performed independent of the administered immunossupressant. The group with GO showed a greater degree of gingival inflammation index. HLA-A68 had greater expression among patients without GO (P = .04). The risk factors for GO occurrence were evaluated using a multivariate analysis that identified gingival inflammation and HLA-A24 expression as risk factors. Increased age and use of TAC were identified as protective factors. GO showed a high prevalence, yet a light intensity. Patients who were younger, men, or received CsA showed a greater occurrence of GO. The risk factors identified for GO development were the presence of gingival inflammation and HLA-A24 expression.
Lima
R B
RB
School of Medicine Sciences of Santa Casa of São Paulo, São Paulo, Brazil.
Benini
V
V
Sens
Y A S
YA
D000328:Adult; D002121:Calcium Channel Blockers / Q000378:metabolism; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005881:Gingiva / Q000473:pathology*; D005885:Gingival Hyperplasia / Q000453:epidemiology*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010510:Periodontal Diseases / Q000453:epidemiology*; D015995:Prevalence
D002121:Calcium Channel Blockers; D006680:HLA Antigens; D016572:Cyclosporine